Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001341571 | SCV001535451 | uncertain significance | not provided | 2018-09-26 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The serine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with SPG20-related disease. ClinVar contains an entry for this variant (Variation ID: 240963). This variant is present in population databases (rs368305530, ExAC 0.01%). This sequence change replaces asparagine with serine at codon 376 of the SPG20 protein (p.Asn376Ser). The asparagine residue is weakly conserved and there is a small physicochemical difference between asparagine and serine. |
| Genome Diagnostics Laboratory, |
RCV001847991 | SCV002105790 | uncertain significance | Hereditary spastic paraplegia | 2016-12-12 | criteria provided, single submitter | clinical testing |